FR0013426004 - Common Stock

Overall **CLA** gets a fundamental rating of **3** out of 10. We evaluated **CLA** against 96 industry peers in the **Software** industry. While **CLA** is still in line with the averages on profitability rating, there are concerns on its financial health. **CLA** has a decent growth rate and is not valued too expensively.

In the past year **CLA** had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: **CLA** reported negative net income in multiple years.

With a **Return On Assets** value of **-4.01%**, **CLA** is not doing good in the industry: **73.81%** of the companies in the same industry are doing better.

Looking at the **Return On Invested Capital**, with a value of **21.67%**, **CLA** belongs to the top of the industry, outperforming **91.67%** of the companies in the same industry.

Measured over the past 3 years, the **Average Return On Invested Capital** for **CLA** is above the industry average of **10.46%**.

The 3 year average ROIC (**13.37%**) for **CLA** is below the current ROIC(**21.67%**), indicating increased profibility in the last year.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -4.01% | ||

ROE | N/A | ||

ROIC | 21.67% |

ROA(3y)-1.22%

ROA(5y)-5.39%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)13.37%

ROIC(5y)10.65%

In the last couple of years the **Operating Margin** of **CLA** has grown nicely.

In the last couple of years the **Gross Margin** of **CLA** has remained more or less at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 5.13% | ||

PM (TTM) | N/A | ||

GM | 24.64% |

OM growth 3Y21.32%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.27%

GM growth 5Y0.82%

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), **CLA** is creating value.

The number of shares outstanding for **CLA** has been reduced compared to 1 year ago.

Compared to 5 years ago, **CLA** has more shares outstanding

Compared to 1 year ago, **CLA** has a worse debt to assets ratio.

Based on the Altman-Z score of **1.08**, we must say that **CLA** is in the distress zone and has some risk of bankruptcy.

With a **Altman-Z score** value of **1.08**, **CLA** is not doing good in the industry: **73.81%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | N/A | ||

Altman-Z | 1.08 |

ROIC/WACC3.35

WACC6.47%

A Current Ratio of **0.64** indicates that **CLA** may have some problems paying its short term obligations.

Looking at the **Quick ratio**, with a value of **0.52**, **CLA** is doing worse than **96.43%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 0.64 | ||

Quick Ratio | 0.52 |

Measured over the past years, **CLA** shows a very strong growth in **Revenue**. The Revenue has been growing by **25.71%** on average per year.

EPS 1Y (TTM)30.3%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q60.53%

Revenue 1Y (TTM)7.23%

Revenue growth 3Y7.41%

Revenue growth 5Y25.71%

Revenue growth Q2Q-0.36%

Based on estimates for the next years, **CLA** will show a very strong growth in **Earnings Per Share**. The EPS will grow by **408.74%** on average per year.

The **Revenue** is expected to grow by **3.79%** on average over the next years.

EPS Next Y5233.33%

EPS Next 2Y877.53%

EPS Next 3Y408.74%

EPS Next 5YN/A

Revenue Next Year0.31%

Revenue Next 2Y3.08%

Revenue Next 3Y3.79%

Revenue Next 5YN/A

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The **Price/Earnings Ratio** is negative for **CLA**. In the last year negative earnings were reported.

With a **Price/Forward Earnings** ratio of **16.40**, **CLA** is valued correctly.

78.57% of the companies in the same industry are more expensive than **CLA**, based on the **Price/Forward Earnings** ratio.

Compared to an average S&P500 **Price/Forward Earnings** ratio of **21.63**, **CLA** is valued a bit cheaper.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 16.4 |

Based on the **Enterprise Value to EBITDA** ratio, **CLA** is valued cheaper than 89.29% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | 7.38 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as **CLA**'s earnings are expected to grow with **408.74%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y877.53%

EPS Next 3Y408.74%

No dividends for **CLA**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**CLARANOVA SE**

EPA:CLA (2/23/2024, 7:00:00 PM)

**2.65**

**-0.1 (-3.81%) **

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupSoftware & Services

GICS IndustrySoftware

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap150.32M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 16.4 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -4.01% | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 5.13% | ||

PM (TTM) | N/A | ||

GM | 24.64% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.92

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 0.64 | ||

Quick Ratio | 0.52 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)30.3%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y5233.33%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)7.23%

Revenue growth 3Y7.41%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y